| Overview |
| bs-13265R-Cy5.5 |
| GALE/Galactowaldenase Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Pig, Horse |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GALE/Galactowaldenase |
| 21-120/348 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2582 |
| Cytoplasm |
| FLJ95174; FLJ97302; Galactose 4 epimerase UDP; Galactowaldenase; galE; GALE_HUMAN; OTTHUMP00000002991; OTTHUMP00000002994; OTTHUMP00000037931; OTTHUMP00000044857; SDR1E1; short chain dehydrogenase/reductase family 1E member 1; UDP galactose 4 epimerase; UDP glucose 4 epimerase; UDP-galactose 4-epimerase; UDP-glucose 4-epimerase. |
| GALE is a 348 amino acid protein that functions as the third enzyme in the Leloir pathway of galactose metabolism. A member of the sugar epimerase family, GALE exists as a homodimer, binds FAD as a cofactor and catalyzes the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine and UDP-glucose to UDP-galactose. The gene encoding GALE maps to human chromosome 1p36.11 and mutations in this gene lead to the development of complex disorder known as epimerase-deficiency galactosemia (EDG) or galactosemia type 3, which is characterized by mental retardation, liver damage, cataracts and deafness. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz